ClinicalTrials.gg
CompletedNCT01800032Updated May 12, 2021

PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)

An observational study in Neurofibromatosis-1, Optic Glioma and Plexiform Neurofibroma, sponsored by UNC Lineberger Comprehensive Cancer Center. Completed at 1 site in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2021-05-12.

Sponsored by UNC Lineberger Comprehensive Cancer Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
6 Years and older
Sex
All
01

Study summary

This prospective pilot study is designed to provide preliminary data on the use of Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) in patients with neurofibromatosis-1 (NF1) associated optic glioma and plexiform neurofibroma (PN).

Subjects will undergo FDG-PET-MRI scans in place of standard of care imaging at 0 and 12 months, unless more frequent imaging is clinically indicated. Subjects and their family caregivers will also undergo serial interviews and complete questionnaires related to the psychosocial aspects of NF1.

02

Conditions studied

  • Neurofibromatosis-1
  • Optic Glioma
  • Plexiform Neurofibroma
03

In context

Neurofibroma, Plexiform

63 studies on the registry are indexed under Neurofibroma, Plexiform; 19 are open to participants now.

This study's enrollment of 30 is below the median of 200 across 13 observational studies indexed under Neurofibroma, Plexiform.

Browse Neurofibroma, Plexiform studies →

Lead sponsor

UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 429 studies on the registry; 97 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

UNC Hospitals

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with neurofibromatosis-1 with either optic glioma, due for imaging scan, or plexiform neurofibroma, due for imaging secondary to clinical signs or symptoms of progressive disease
  • ≥ 6 years of age
  • English-speaking
  • If female of , negative urine pregnancy test performed within 7 days prior to each FDG-PET-MRI
  • Study-specific or assent obtained and signed

Exclusion criteria

Exclusion Criteria:

  • Unable to undergo FDG-PET-MRI without sedation
  • Currently undergoing chemotherapy for progressing optic glioma
  • Pregnant or lactating female
  • Poorly controlled diabetes mellitus
  • Presence of pacemaker, intracranial aneurysm clip, cochlear implant, metal halo device, epicardial pacemaker leads, or any other device that makes MRI unsafe
  • Serum creatinine > 1.8 mg/dL OR \< 30 mL/min
  • Unable to lie flat for > 1 hour
  • (BMI) > 35
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • Plexiform Neurofibroma

    NF1 associated plexiform neurofibroma

  • Optic Glioma

    NF1 associated optic glioma

06

What researchers measure

Primary outcomes

  1. Plexiform Neurofibroma Cohort: Difference in FDG-avidity between progressive and non-progressive lesions

    Ratios of SUVmax values within a group of patients who all have progressive disease

    Time frame: 12 months

  2. Optic Glioma Patients: Compare FDG-avidity between patients with progressive and non-progressive disease

    Time frame: 12 months

Secondary outcomes

  1. Report descriptive statistics for FDG-PET-MRI results

    SUV max, tumor/brain uptake ratio, tumor/muscle uptake ratio

    Time frame: 0, 12 months

  2. Explore impact of FDG-PET-MRI surveillance on patient and family caregiver uncertainty and psychological distress

    Time frame: 0, 12 months

07

Study locations

1 site
  • University of North Carolina-Chapel Hill
    Chapel Hill, North Carolina 27599, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in Dec 2018, 70 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2013
First posted
Feb 27, 2013
StartActual
Jan 16, 2013
Primary completionActual
Dec 5, 2018
CompletionActual
Dec 5, 2019
Last update
May 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01800032
Responsible party
Sponsor
First posted
Feb 27, 2013
Start date
Jan 16, 2013
Primary completion
Dec 5, 2018
Completion
Dec 5, 2019
Last update
May 12, 2021

Study contacts

Timothy Gershon, MD, PhD
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion